Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26290447 | 0.79 | SELL (0.41) | TDP1MAPTALDH1A1HSD17B10MAPK1 | |
| SCHEMBL10520286 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HSD17B10POLBMAPK1KDM4E | |
| SCHEMBL31474116 | 0.78 | ALDH1A1 (0.39) | ALDH1A1MAPK1KDM4EHPGD | |
| SCHEMBL6837909 | 0.74 | MAPT (0.47) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL1505827 | 0.73 | TDP1 (0.61) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL10857668 | 0.72 | LMNA (0.42) | TDP1MAPTALDH1A1KDM4E | |
| SCHEMBL30860405 | 0.72 | HIF1A (0.70) | HIF1AHSP90AA1 | |
| SCHEMBL21752804 | 0.72 | HIF1A (0.70) | HIF1AHSP90AA1 | |
| Hydrochloric Acid SCHEMBL2202243 | 0.71 | TDP1 (0.59) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL31474158 | 0.71 | ALDH1A1 (0.43) | MAPTALDH1A1HIF1AHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909575-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | ChemoCentryx Inc (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | CHEMOCENTRYX, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002842-A2 | SUBSTITUTED N-CINNAMYL BENZAMIDES | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021484-A1 | Substituted N-cinnamyl benzamides | BRDT, BCCIP, NAT10 | TDP1 4151/4885MAPT 4491/4885ALDH1A1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.